Erschienen in:
27.05.2023 | IM - COMMENTARY
Direct oral anticoagulants in patients with bioprosthetic heart valves
verfasst von:
Giulia Renda
Erschienen in:
Internal and Emergency Medicine
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Excerpt
Non-vitamin K oral anticoagulants, also known as direct oral anticoagulants (DOACs), due to their direct inhibition of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, and edoxaban) are safe and efficacious alternatives to vitamin K antagonists (VKAs) for the prevention of thromboembolism in atrial fibrillation (AF) and they are recommended in preference to VKAs in AF patients eligible to oral anticoagulants (excluding those with moderate-to-severe mitral stenosis or mechanical heart valves) [
1]. …